Download publications

Kenneth Craig Micetich, M.D.
CURRICULUM VITAE
Kenneth Craig Micetich, M.D.
PERSONAL DATA
Address
2160 South First Avenue
Maywood, IL 60153
Phone Numbers
Work: 708-327-3144
Fax: 708-327-3219
EDUCATION
1965-1969
B.S. Psychology, Loyola University,
Chicago, Illinois
1969-1974
M.D., Loyola University Stritch School of
Medicine, Maywood, Illinois
1972-1973
1974-1975
Graduate Research, Department of
Biochemistry, Loyola University
POSTGRADUATE
1975-1978
Resident in Internal Medicine, Loyola
University Medical Center, J.R. Tobin,
M.D., Chairman
1977-1978
Associate Chief Resident, Dept. of Internal
Medicine, Loyola University Medical Center
1978-1979
Oncology Fellow, Loyola University Medical
Center, Ketty Badrinath, M.D., Chief
1979-1980
Clinical Associate, in Oncology, Medicine
Branch, NCI, NIH, R.C. Young, M.D., Chief
1
Kenneth Craig Micetich, M.D.
1980-1981
Clinical Associate, Laboratory of Molecular
Pharmacology, NCI, NIH, K. Kohn, M.D. Ph.D.,
Chief
POSITIONS
1981-1988
Assistant Professor of Medicine, Loyola
University Stritch School of Medicine,
Division of Hematology/Oncology
1988-1996
Associate Professor of Medicine, Loyola
University Stritch School of Medicine,
Division of Hematology/Oncology
1989-present
Associate Chief, Hospital Ethics Consultation Service
1996-present
Professor of Medicine, Loyola
University Stritch School of Medicine,
Division of Hematology/Oncology
1997-2003
Director, Cancer Genetics Counseling Program
1998-present
Co-Director, GI Oncology Clinic
SOCIETIES
Alpha Sigma Nu National Jesuit Honor Society
American Society of Clinical Oncology
American Association of Cancer Research
LICENSURE
Illinois (36-56032)
2
`
Kenneth Craig Micetich, M.D.
BOARDS
Diplomate of National Board of Medical Examiners (1976)
Diplomate of the American Board of Internal Medicine (1978)
Board Certified in Medical Oncology (1981)
COMMITTEES
1981-1982
1981-1984
Student Promotion Committee
Student Evaluation Committee
1982-1984
Tissue Committee
1982-1984
Research Committee
1982-1984
Multidisciplinary Oncology Committee
1982-present
Institutional Review Board for the Protection
of Human Subjects (Vice-Chairman 1987-1989,
Chairman 1989-present)
1982-1987
Postgraduate Education Committee
1984-1987
Hospital Medical Record Committee
1984-1985
Co-chairman, New Agent Committee,
Illinois Cancer Council
1985-1987
Chairman, New Agent Committee,
Illinois Cancer Council
1986-1988
Chairman, Committee on Medical School
Admissions
1986-1990
Grant Review Committee, Leukemia Research
Foundation
1986-1990
Lung Cancer Committee, Southwest Oncology
Cooperative Group
3
Kenneth Craig Micetich, M.D.
1986-2003
Training Program Director, Divison of Hematology-Oncology
1987-2004
Radioactive Research Committee
1988-1990
Chairman, Adverse Drug Reaction Committee
1988-2003
Chairman, Hematology/Oncology
Fellow Evaluation Committee
1988-present
Hospital Ethics Committee (Chairman, 1997 to present)
1991-2000
Advisory Board, Center for Ethics across the
University
1994-1999
Member, Central Curricular Authority
1994-1999
Member, Design Subcommittee
1994-1995
Chairman, Cell and Molecular Biology Task
Force
1995-1996
Co-Chair, Clinical Experiences Task Force
1996-2000
Clinical Practice Committee
2006-2008
Streamlining Research Committee
2004-2006
Director, Loyola University Physicians Foundation
2006-2009
Director, Midwest Regional Educational Laboratory (MREL)
2006-2009
Tissue Bank Oversight Committee
2011-present
Conflict of Interest Committee
2014-present
University Committee on Rank and Tenure
4
Kenneth Craig Micetich, M.D.
EDITORIAL BOARDS
Editorial Board of Theoretical Medicine (expired 2003)
Editorial Board of Accountability in Research (term expired 2013)
FACULTY
Faculty member, Section of Medical Humanities
Faculty member, Department of Medicine, Division of Hematology-Oncology
Faculty Member, Graduate School, Loyola University Chicago
COURSES TAUGHT
1.
2.
3.
4.
5.
6.
Medical Ethics
Medical Pharmacology
Organ Systems
Introduction to the Practice of Medicine
Medicine I and II
Rotation co-developer and co-director: Multidisciplinary
Oncology Outpatient for Medical Students and Medical Residents
7. Reflections course, PCM 3
GRANTS AND AWARDS
1. Chicago Community Trust: 4/1/85 to 4/30/87. A Comparative Study of Cisdiamminedichloroplatinum(II)andcis-(diammino)(1,1-cyclobutanedicar- boxylato)platinum (II) Treatment of L1210 Cells: The Effects of Drug Solvent, Extracellular
Chloride Ion Concentration and AGe of Drug Solution. $100,000.00
2. Recipient of the American Cancer Society Clinical Oncology Career Development
Awards, 7/85-6/88. $95,000.00
3. Co-investigator, Bristol Drug Resistance Program.
$1,000,000.00
4. Richard A. Perritt Charitable Foundation for Gastrointestinal Cancer Research and
Education.
$ 350,000.00
5. Damen Award, Loyola University Chicago, 2007.
5
Kenneth Craig Micetich, M.D.
RESEARCH INTERESTS
Research interests include development and testing of clinical strategies to overcome
antineoplastic drug resistance; the theory of adjuvant therapy; scientific, research and medical
ethics; medical education at the graduate and undergraduate level
ABSTRACTS
1.
Micetich, K.C., Michaels, S., Jude, G., Zwelling, L.A., and Kohn, K.W. Mechanism
of resistant to Cis-diamminedichloro-platinum (II) in a line of L1210 cells. Amer
Asscn Cancer Res., 22:252, 1981.
2.
Micetich, K.C., Erickson, L.C., Gormley, P., Zwelling, L.A. m-AMSA serum levels
vs. m-AMSA indirect lymphocyte (PBL) DNA breakage as an indicator of delivered
drug during a phase I-II trial of continuous infusion of m-AMSA. Amer Asscn
Cancer Res., 23:202, 1982.
3.
Collins, S., Delfanti, B., Creekmore, S., Micetich, K.C., Miller, J.B., Choudhury, A.,
and Matz, G. Pilot study results of anterior chemotherapy using Cis-platinum and 5FU for advanced head and neck squamous cell carcinoma. Int Conf on Head and
Neck Cancer, Baltimore, July 22-27-, 1984.
4.
Creekmore, S., Micetich, K.C., Vogelzang, N., Canzoneri, C., Choudhury, A., and
Fisher, R.I. Low toxicity and significant tumor responses in Phase II trials of
Carboplatin (CBDCA) in head and neck, non-small cell lung, urothelial, and ovarian
cancers. Proc Soc Clin Onc., 4144, 1985.
5.
Micetich, K.C., Barnes, D., Erickson, L.C. A comparison of the cytotoxicity and
DNA damaging effects of Cis-(diammino) 1,1-cyclobutanedicarboxylato) platinum
(II) CBDCA) and cis-diamminodichloroplatinum (II) (DDP) on L1210 cells. Amer
Asscn Cancer Res., 26:264, 1985.
6.
Micetich, K.C., Barnes, D. Clark, J., Erickson, L.C. Extracellular chloride ion
modulates the cytotoxicity and DNA damaging effects of cisdiamminodichloroplatinum (II) (DDP) on L1210 cells. Amer Asscn Cancer Res.,
27:228, 1986.
7.
Creekmore, S.P., Waters, W.B., Vogelzang, N.J., Micetich, K.C., Fisher, R.I.
6
Kenneth Craig Micetich, M.D.
Antitumor activity of 24 hour CBDCA infusions in metastatic transitional cell
carcinoma. Amer Soc Clin Oncology, 5:101, 1986.
8.
Behr, J.T., Hall, R.F., Dobozi, W.R., Smith, D.G., Micetich, K.C., Badrinath, K.
Closed Intramedullary biopsy of metastatic carcinoma. 19th Annual American
Orthopedics Research Conf, Los Angeles, May l, 1986.
9.
Rayner, A.A., Lionetta, R., Atkins, M.B., Ciobanu, N., Micetich, K.C., Weiss, G.R.,
Doroshow, J.H. Phase II trial of Interleukin-2 bolus priming followed by continuous
infusion with lymphokine activated killer cells (IL2/LAK) in metastatic melanoma.
Proc of Amer Soc Clin Oncology, 7, 246, 1988.
10. Micetich, K.C., Erickson, L.C., and Fisher, R.I. A Phase I trial of Streptozotocin
(STX) followed by BCNU. Amer Asscn Cancer Res., 30:275, 1989
11. McCall, A., and Micetich, K.C. Multidisciplinary medical student outpatient
oncology rotation. Amer Asscn for Cancer Education, October, 1996.
12.
Kindler H, Bylow K, Hochster H, Friberg G, Micetich K, Locker G, et al. A
randomized phase II study of bevacizumab and gemcitabine plus cetuximab or
erlotinib in patients with advanced pancreatic cancer: A preliminary analysis. ASCO
Annual Meeting 2006; Abs 4040.
13. Kindler, H. L., Gangadhar, T., Karrison, T., Hochster,H.S., Moore, M.J., Micetich,
K., Sun, W., Catenacci, D.V., Stadler, W.M., Vokes, E.E.. Final analysis of a
randomized phase II study of bevacizumab (B) and gemcitabine (G) with cetuximab
(C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC) ASCO
Meeting Abstracts 2008 26: 4502
14. Shoup, M., Nagda, S., Micetich, K., Malhotra, D., Drakes, M., Borge, M., Stiff, P.
A novel dendritic cell (DC) immunotherapy trial for locally advanced pancreatic
cancer (PC). ASCO- GI, January 2010, abstract 413.
15. Anthony B. El-Khoueiry, A.B., Rankin, C., Iqbal, S., Micetich, K.C., Kayaleh, O.,
Lenz, H.D., Blanke, C.D. A phase II study of sorafenib and erlotinib in patients (pts)
with advanced gallbladder cancer or cholangiocarcinoma. J Clin Oncol 30, 2012
(suppl; abstr 4113)
16. Brandt, W., Yong, S., Abood, G., Micetich, K., Walther, A., Shoup, M. The Depth
7
Kenneth Craig Micetich, M.D.
of Post-Treatment Subserosal Invasion is a Predictor of Outcome in
Patients with Clinical Stage III Rectal Cancer Treated with Neoadjuvant
Chemoradiation followed by Surgical Resection. Midwest Meeting, July
2013.
17. Ben-Josef, B., Guthrie, K., El-Khouiery, A.B., Corless, C.L., Zalupski, M., Lowy,
A.M., Thomas, C.B., Alberts, S.R., Dawson, L.A., Micetich, K.C., Thomas, M.B.,
Siegel, A.B., Blanke, C.D. SWOG S0809: A phase II trial of adjuvant capecitabine
(cap)/gemcitabine(gem) followed vby concurrent capecitabine and radiotherapy in
extrhepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBCA). J Clin
Oncol 32: 5s, 2014 (suppl; abstr 4030).
18. Shah, F., Silverman, D., Doloto, P., Micetich, K.C., Barron, J.T.Abstract 1461: Serial
Echocardiography for early diagnosis of cardiotoxicity in breast cancer patients treated
with trastuzumab. 19th World Congree on Heart Disease, Boston, MA. July 25-28,
2014.
PUBLICATIONS
1.
Micetich, K.C., Jensen-Akula, M., Mawdard, J.C., and Fisher, R.I. Nephrotoxicity
of Semustine (Methyl-CCNU) in patients with malignant melanoma receiving
adjuvant chemotherapy. Am J Med, 71:967-972, 1981.
2.
Hoofnagle, J.H., Dusheiko, G.M., Schafer, D.F., Jones, E.A., Micetich, K.C., Young,
R.C., Costa, J. Reactivation of chronic hepatitis B virus infection by cancer
chemotherapy. Ann Int Med., 96:447-449, 1982.
3.
Micetich, K.C., Zwelling, L.A., Gormley, P., Young, R.C. A Phase I-II study of mAMSA administered as a continuous infusion. Cancer Treat Rep., 66:1813-1817,
1982.
4.
Micetich, K.C. The chemotherapy of small cell cancer of the lung. Phil Am Med
Bull, 1982.
5.
Micetich, K.C., Steinecker, P.H., Thomasma, D. Are IV fluids morally required for
the dying patient? Arch Internal Med., 143:975-978, 1983.
6.
Micetich, K.C., Zwelling, L.A., Kohn, K.W. Quenching of DNA Platinum (II)
8
Kenneth Craig Micetich, M.D.
monoadducts as a possible mechanism of resistance to Cisdiamminedichloroplatinum
(II) in L1210 cells. Cancer Res., 43:3609-3613, 1983.
7.
Micetich, K.C., Thomasma, D. The ethics of patient requests in experimental
medicine. Ca-Journal for clinicians, 34:118-120, 1984.
8.
Ko-Shan, C.S., Micetich, K.C., Zwelling, L.A., Whang-Peng, J. Cytogenetic effects
of Amsacrine in human lymphocytes in vivo and in vitro. Cancer Treat Rep., 68:
989-997, 1984.
9.
Micetich, K.C., Barnes, D., Erickson, L.C. A comparative study of the cytotoxicity
and DNA damaging effects of cis-(diammino) 1,1-cyclobutanedicarboxylato)platinum(II) and cis- diamminedichloro-platinum (II) on L1210 cells. Cancer Res.,
45:4043-4047, 1985
10.
Perry, D.J., Weiss, R.B., Creekmore, S.P., Micetich, K.C., Curt, G.A. Carboplatin
for advanced colorectal cancer. A phase II study. Cancer Treat. Reports, 70:301302, 1986.
11.
Dudley, K., Micetich, K.C., Massa, M.C. Facial erythema with features of
seborrheic dermatitis and lupus erythematosis associated with the administration of
systemic 5-fluorouracil. Cutis, 39:64-66, 1987.
12.
Thomasma, D.C., Micetich, K.C., Steinecker, P.H. Continuance of nutritional care
in the terminally ill patient. Critical Care Clinics, 2:61-71, 1986.
13.
Thomasma, D.C., Micetich, K.C., Steinecker, P.H. Social censorship of medical and
ethical decisions. Pharos, 48:22-26, 1985.
14.
Micetich, K.C., Steinecker, P.H., Thomasma, D. An empirical study of physician
attitudes. In By No Extraordinary Means: The Choice to Forgo Life-Sustaining Food
and Water. Ed by Joanne Lynn, M.D. P39-42. Indiana University Press, 1986.
15.
Erickson, L.C., Micetich, K.C., Fisher, R.I. Preclinical and clinical experiences
with inhibitors of DNA repair in resistant human tumor cells. In P.V. Wooley, III,
and K.D. Tew (eds). Mechanisms of Drug Resistance in Neoplastic Cells. Academic
Press, NewYork. PP173-183, 1988.
16.
Micetich, K.C., Gruber, A., Steinecker, P.H. Intravenous fluid and nutritional
9
Kenneth Craig Micetich, M.D.
therapies and the chronically ill patient. In Monagle, J.F. and Thomasma, D.C. (eds).
Medical Ethics. A Guide for Health Professionals. Aspen Publishers, Rockville,
MD.PP178-184,198817.
17.
Futscher, B.W., Micetich, K.C., Barnes, D.M., Fisher, R.I., and Erickson, L.C.
Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant
human cancer cells. Cancer Communications, 1:65-73, 1989.
18.
Kolbusz, R.V., Micetich, K., Armin, A.R., and Massa, M.C. Exaggerated response to
Insect bites. An unusual cutaneous manifestation of chronic lymphocytic leukemia.
Int J Dermatology, 28: 186-187, 1989.
19.
Micetich, K.C., Creekmore, S.P. and Fisher, R.I. A Phase II study of a twenty-four
infusion of carboplatin in patients with non-small cell lung cancer. In Carboplatin
(JM-8) Current Perspectives and Future Directions. Ed. Bunn, P.A., Canetta, R.,
Ozols, R.F., Rozencweig, M. W.B. Saunders Company, Philadelphia, 1990. PP 317322.
Micetich, K.C., Creekmore, S.P., Vogelzang, N., and Fisher, R.I. A Phase II study
of a twenty-four hour infusion of carboplatin in patients with advanced transitional
cell carcinoma of the urinary tract. In Carboplatin (JM-8) Current Perspectives and
Future Directions. Ed. Bunn, P.A., Canetta, R., Philadelphia, 1990. PP.83-92.
20.
21.
Bar, M.H., Sznol, M., Atkins, M.B., Ciobanu, N., Micetich, K.C., Boldt, D.H., and
et al. Metastatic malignant melanoma treated with combined bolus and continuous
infusion Interleukin-2 and lymphokine activated killer cells. J Clin Onc 8:11381147, 1990.
22.
Micetich, K.C., Futscher, B., Koch, D., Fisher, R.I., and Erickson, L.C. A phase I
Study of Streptozotocin and BCNU sequence administration in patients with advance
cancer. JNCI 84: 256-260, 1992.
23.
Sparano, J.A., Fisher, R.I., Sunderland, M., Margolin, K., Ernest, M.L., Sznol, M.,
Atkins, M.B., Dutcher, J.P., Micetich, K.C., Weiss, G.P., Doroshow, J.H., Aronson,
F.R., Rubinstein, L.V., and Mier, J.W.: A randomized Phase III trial of treatment
with high dose interleukin-2 either alone or in combination with interferon-alpha in
patients with advanced melanoma. J Clin Oncol 11: 1969-1977, 1993.
24.
Micetich, K.C. Reflections of an IRB Chair. Cambridge Quart Health Care Ethics
4, 506-509, 1994.
10
Kenneth Craig Micetich, M.D.
25.
Micetich, K.C. Clinical Applications of Oncological Nuclear Medicine. In Nuclear
Medicine, Principles and Practice, ed by Henkin, RE et al, Mosby Year Book, pges
1461-1462. St. Louis, MO, 1996.
26.
Micetich, K.C. The Ethical Problems of the Open-Label Extension Study.
Cambridge Quarterly of Health Care Ethics. Cambridge Quart Health Care Ethics
5, 410-414, 1996.
27.
Micetich, K.C. The IRB: Current and Future Challenges. In Monagle, J.F. and
Thomasma, D.C. (eds). Health Care Ethics. Critical Issues for the 21st Century.
Aspen Publishers, Rockville, MD. PP 265-276, 1998.
28.
Micetich, K.C. End of Life Issues at the Millenium: What Have We Done and
Where are We Going?. Proceedings of the International Association of Catholic
Medical Schools, University of Santo Tomas, ed. Fausto Gomez, O.P., 1999.
29.
Thomasma, D.C., Micetich, K.C., Brems, J. Van Thiel, D. The ethics of
competition in liver transplantation. Cambridge Quart Health Care Ethics 8, 321329, 1999.
30.
Mason, G.R., Micetich, K., Aranha, G.V. Long-term survival of a patient with
widespread metastases from Barrett’s adenocarcinoma. European Journal of Surgical
Oncology 27:509-514, 2001.
31. Gordon, E., Micetich K.C. Competing clinical trials in the same institution: ethical
issues in subject selection and informed consent. IRB 24, 1-6, 2002.
32. Paner, G.P., Silberman, S., Hartman,G., Micetich, K.C., Aranha, G.V., Alkan, S.
Analysis of signal transducer and activator of transcription 3 (STAT3) in
gastrointestinal stromal tumors. Anticancer Res 23:2253-60, 2003.
33. Micetich, K.C., Clinical Applications of Oncological Nuclear Medicine. In Nuclear
Medicine, ed Henkin et al. Mosby, 2006. pp 1439-1441.
34. Micetich, K.C. Is artifical nutrition and hydration extraordinary care? Virtual
Mentor 9: 340-344, 2007.
35. Sobol, U.A., Sherman, K.L., Smith, J., Nagda, S.N., Miceich, K., Nickoloff, B.J.,
Shoup, M.C. Sweet’s syndrome with neurologic manifestations in a patient with
11
Kenneth Craig Micetich, M.D.
esophageal adenocarcinoma: case report and review of the literature.
Dermatolo 48: 1062-1065, 2009.
Int J
36. El-Khoueiry, A.B., Rankin, C., Siegel, A.B., Iqbal, S., Gong, I.Y., Micetich,
K.C., Kayaleh, O.R., Lenz, H.J., Blanke, C.D.. S0941: a phase 2 SWOG study of
sorafenib and erlotinib in patients with advanced gallbladder carcinoma or
cholangiocarcinoma. British Journal of Cancer 110, 882-887, 2014.
37. Brandt, WS., Yong,S.,Abood,G., Micetich, K., Walther,A and Shoup, M. The
depth of post-treatment perirectal tissue invasion is a predictor of outcom ein
patients with clinical T3N1M0 rectal cancer treated with neoadjuvant
chemoradiation followed by surgical resection. Am J Surg 2014, 357-360, 2014.
38. Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy
AM, Thomas CR Jr, Alberts SR, Dawson LA, Micetich KC, Thomas MB, Siegel
AB, Blanke CD. SWOG S0809: A Phase II Intergroup Trial of Adjuvant
Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent
Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J
Clin Oncol. 2015 Aug 20;33(24):2617-22.
.
September, 2016
12